Answers are grounded in this paper and cite their sources.
Target trial analysis assesses intravenous thrombolysis in patients on direct oral anticoagulants, highlighting safety without prior anticoagulation reversal therapy.
This study aimed to report the safety and efficacy of off-label intravenous thrombolysis (IVT) with alteplase after sequentially liberalizing our institutional guidelines allowing IVT for patients under direct oral anticoagulants (DOACs) regardless of plasma levels, time of last intake, and without prior anticoagulation reversal therapy.
No takes yet. Share an insight, caveat, or question.
Bücke et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: